Charles River Laboratories Sells Off $200M in European and CDMO Assets
Event summary
- Charles River Laboratories has signed agreements to divest its CDMO and Cell Solutions businesses to GI Partners, and certain European Discovery Services assets to IQVIA for $145M in cash.
- The divestitures include five European sites and will reduce 2026 revenue by over $200M, but are expected to improve non-GAAP operating margins by at least 100 basis points.
- The transactions are set to close in Q2 2026, subject to customary closing conditions.
- The CDMO and Cell Solutions businesses generated $143M in combined annual revenue in 2025, while the European Discovery Services assets generated $144M.
The big picture
Charles River Laboratories is streamlining its portfolio by divesting non-core assets, a move that reflects broader industry trends toward specialization and operational efficiency. The transactions, totaling over $200M in revenue impact, are part of a comprehensive strategic review aimed at enhancing shareholder value and long-term growth. The divestitures highlight the company's focus on core capabilities that align with its broader portfolio, particularly in the biotechnology and pharmaceutical services sectors.
What we're watching
- Portfolio Focus
- How Charles River's divestitures will refine its core capabilities and drive synergistic growth with its broader portfolio.
- Financial Impact
- Whether the expected 100 basis points of incremental non-GAAP operating margin improvement will materialize as planned.
- Execution Risk
- The pace at which Charles River can integrate the strategic changes and maintain operational excellence post-divestiture.
Related topics